We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ABL Bio

News List

ABL Bio and Sanofi partner to develop antibody for Parkinson’s disease Pharmaceutical-Technology
January 13, 2022
ABL Bio will receive $985m in milestone payments from Sanofi in addition to royalties on the net sales of the product.
HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19 pharmaceutical-business-review
September 17, 2020
HiFiBiO Therapeutics has entered into a partnership with South Korea-based ABL Bio to co-develop its SARS-CoV-2 neutralising antibody HFB30132A for the treatment of Covid-19.
I-Mab Biopharma, ABL Bio collaborate for innovative bispecific Abs biospectrumasia
July 30, 2018
Under the terms of the agreement, ABL Bio will pay $2.5 million in upfront payment.